ChemoCentryx: Avacopan's Attractive Value Proposition
Seeking Alpha,
Introduction A lot has happened at ChemoCentryx (NASDAQ: CCXI ) since my first report back in November 2017.
Introduction A lot has happened at ChemoCentryx (NASDAQ: CCXI ) since my first report back in November 2017.
Summary InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for…